Clinical Trials Directory

Trials / Completed

CompletedNCT06403449

The Effectiveness of Group-Delivered Guided Written Exposure Therapy for PTSD and Subclinical PTSD Among Adolescents : a Pilot Study

The Effectiveness of Group-Delivered Guided Written Exposure Therapy for PTSD and Subclinical PTSD Among Chinese Adolescents: a Pilot Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Peking University · Academic / Other
Sex
All
Age
10 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The study aims to examine the effectiveness of the group-delivered guided written exposure therapy (G-WET) for post-traumatic stress disorder (PTSD) and subclinical PTSD among Chinese adolescents with a randomized controlled trial. The study will recruit 40 participants, with 20 randomized to the G-WET group and 20 randomized to the waiting list (WL) group. The G-WET intervention consists of 5-8 group sessions. The primary outcome PCL-5 ( PTSD Checklist-5) will be administered on baseline, post-treatment, 1-month follow-up, 3-month follow-up assessments.

Conditions

Interventions

TypeNameDescription
BEHAVIORALGroup-delivered guided written exposure therapy-revised versionGroup-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
BEHAVIORALWaiting-List (WL) conditionParticipants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.

Timeline

Start date
2024-05-10
Primary completion
2024-10-15
Completion
2024-10-15
First posted
2024-05-07
Last updated
2024-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06403449. Inclusion in this directory is not an endorsement.